Chronic respiratory disease and tobacco consumption. Review
https://doi.org/10.21518/2079-701X-2016-17-144-152
Abstract
Chronic respiratory diseases (CRD), and in particular chronic obstructive pulmonary disease (COPD), pose a relevant healthcare and social problem globally, reflecting the upward trend in the morbidity and mortality from diseases related to tobacco consumption. Tobacco smoking is the main and only modifiable risk factor for the development of CRD including COPD. The current understanding of the problem suggests that COPD develops in 50% of tobacco users and not in 15% as previously thought; that the disease may have originated even before birth or in early childhood; that capturing the mechanisms of the disease development is essential for timely prevention. Prevention of CRD, particularly COPD, should be aimed at overcoming tobacco consumption and take into account all the other risk factors for these diseases. The current smoking cessation treatments involve behavior counselling in combination with first-line pharmacotherapies such as NCT or varenicline. Patients with COPD need greater support than healthy smokers, and interventions for cessation of tobacco consumption are the most cost-effective in reducing the rates of the lung function deterioration and decreasing morbidity and mortality from the disease.
About the Author
M. G. Gambaryan
National Research Center for Preventive Medicine, MoH RF
Russian Federation
PhD in Medicine
Russian Federation
PhD in Medicine
References
1. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet, 2007, 370: 765-773.
2. Buist AS, Vollmer WM, McBurnie MA. Worldwide burden of COPD in high- and lowincome countries. Part I. The Burden of Obstructive Lung Disease (BOLD) Initiative. Int. J. Tuberc. Lung Dis., 2008, 12: 703-708.
3. Lopez AD, Mathers CD. Measuring the global burden of disease and epidemiological transitions: 2002–2030. Ann. Trop. Med. Parasitol., 2006, 100: 481-99.
4. Lopez-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology, 2016, 21: 14-23. doi: 10.1111/resp.12660.
5. Causes of death statistics, Data from September 2012 http://epp.eurostat.ec.europa. eu/statistics_explained/index.php/Causes_of_ death_statistics.
6. Global Health Observatory (GHO), http://www. who.int/gho/countries/rus/country_profiles/en/ index.html.
7. 2013-2020, Global action plan for the prevention and control of noncommunicable diseases, WHO, http://www.who.int/global-coordinationmechanism/publications/global-action-planncds-eng.pdf.
8. Marsh S, Aldington S, Shirtcliffe P, Weatherall M, Beasley R. Smoking and COPD: what really are the risks? Eur. Respir. J., 2006, 28: 883-886.
9. Rennard SI, Vestbo J. COPD: the dangerous underestimate of 15%. Lancet, 2006, 367: 1216-1219.
10. Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких (GOLD), пересмотр 2014 г.
11. Lundback B, Lindberg A, Lindstrom M, Rönmark E, Jonsson AC, Jönsson E, Larsson LG, Andersson S, Sandström T, Larsson K. Not 15 but 50% of smokers develop COPD? Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir. Med., 2003, 97: 115-122.
12. Postma DS, Bush A, van den Berge M. Risk factors and early origins of chronic obstructive pulmonary disease. Lancet, 2015, 385: 899-909.
13. Гамбарян М.Г., Калинина А.М., Дидковский Н.А., Оганов Р.Г. Факторы риска развития хронических обструктивных болезней легких: управление риском, связанным с курением табака. Профилактика заболеваний и укрепление здоровья, 2003, 1: 30-36.
14. Ghambarian MH, Kalinina AM, Feenstra T, Zwanikken P. COPD: can prevention be improved? Proposal for an integrated intervention strategy. Preventive Medicine, 2004, 39: 337-343.
15. Гамбарян М.Г., Дидковский Н.А.,Калинина А.М., Деев А.Д. Факторы риска хронической обструктивной болезни легких, их взаимосвязь и прогностическая значимость. Пульмонология, 2006, 3: 72-76.
16. Eisner MD, Balmes J, Katz BP, Trupin L, Yelin E, Blanc P. Lifetime environmental tobacco smoke exposure and the risk of chronic obstructive pulmonary disease. Environ. Health Perspect, 2005, 4: 7-15.
17. Сюрин С.А., Никанов А.Н., Рочева И.И., Панычев Д.В. Роль курения в развитии бронхолегочной патологии у рабочих никелевого производства. Медицина труда и промышленная экология, 2007, 4: 44-46.
18. Гамбарян М.Г., Калинина А.М., Шальнова С.А., Деев А.Д., Дидковский Н.А. Эпидемиологи чес- кие особенности хронических респираторных заболеваний в разных климатогеографических регионах России. Пульмонология, 2014, 3: 55-61.
19. Гамбарян М.Г., Эпидемиологические особенности хронических респираторных заболеваний в ряде регионов российской Арктики с развитым промышленным производством. Обзор. Профилактическая медицина, 2014, 17(6): 71-78.
20. Гамбарян М.Г., Калинина А.М., Шальнова С.А., Смирнова М.И., Деев А.Д. Изучение эпидемиологических особенностей хронических респираторных заболеваний в зависимости от региона проживания в России. Профилактическая медицина, 2015, 18(1): 14-20.
21. Fischer BM, Pavlisko E, Voynow JA. Pathogenic triad in COPD: oxidative stress, protease–antiprotease imbalance, and inflammation. International Journal of Chronic Obstructive Pulmonary Disease, 2011, 6: 413-421. doi:10.2147/COPD.S10770.
22. Saetta M. Airway Inflammation in Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med., 1999, 160: 17-20.
23. Saetta M, Di Stefano A, Maestrelli P, Ferraresso A, Drigo R, Potena A, Ciaccia A, Fabbri LM. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am. Rev. Respir. Dis., 1993, 147: 301-306.
24. Rutgers SR, Postma DS, ten Hacken NH, Kauffman H, van der Mark TW, Koeter G, Timens W. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax, 2000, 55: 12-18.
25. Agusti A, Macnee W, Donaldson K, Cosio M. Hypothesis: does COPD have an autoimmune component? Thorax, 2003, 58: 832-834.
26. Cosio MG. Autoimmunity, T-cells and STAT-4 in the pathogenesis of chronic obstructive pulmonary disease. Eur. Respir. J., 2004, 24: 3-5.
27. Senn O, Russi EW, Imboden M, Probst-Hensch NM. α1-Antitrypsin deficiency and lung disease: risk modification by occupational and environmental inhalants. European Respiratory Journal Nov, 2005, 26(5): 909-917. DOI: 10.1183/09031936.05.00021605.
28. Stoller JK, Aboussouan LS. A review of a1-antitrypsin deficiency. Am J Respir Crit Care Med, 2012 Feb 1, 185(3): 246-59.
29. van den Berge M, Vonk JM, Gosman M, et al. Clinical and infl ammatory determinants of bronchial hyperresponsiveness in COPD. Eur Respir J, 2012, 40: 1098-105.
30. Tashkin DP, Altose MD, Bleecker ER et al. and the The Lung Health Study Research Group. The lung health study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airfl ow limitation. Am Rev Respir Dis, 1992, 145: 301-10.
31. Tashkin DP, Altose MD, Connett JE, Kanner RE, Lee WW, Wise RA, and the Lung Health Study Research Group. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 1996, 153: 1802-11.
32. Li YF, Langholz B, Salam MT, Gilliland FD. Maternal and grandmaternal smoking patterns are associated with early childhood asthma. Chest, 2005, 127: 1232-41.
33. Marcon A, Cerveri I, Wjst M et al. Can an airway challenge testpredict respiratory diseases? A population-based international study. J Allergy Clin Immunol, 2014, 133: 104-10.e1–4.
34. Van Den Berge M, Meijer RJ, Kerstjens HAM, et al. PC(20) adenosine 5´-monophosphate is more closely associated with airway inflammation in asthma than PC(20) methacholine. Am J Respir Crit Care Med, 2001, 163: 1546-50.
35. van den Berge M, Kerstjens HAM, Meijer RJ, et al. Corticosteroidinduced improvement in the PC20 of adenosine monophosphate is more closely associated with reduction in airway infl ammation than improvement in the PC20 of methacholine. Am J Respir Crit Care Med, 2001, 164: 1127-32.
36. Hardaker KM, Downie SR, Kermode JA, Berend N, King GG, Salome CM. Ventilation heterogeneity is associated with airway responsiveness in asthma but not COPD. Respir Physiol Neurobiol, 2013, 189: 106-11.
37. Palmer LJ, Rye PJ, Gibson NA, Burton PR, Landau LI, Lesouef PN. Airway responsiveness in early infancy predicts asthma, lung function, and respiratory symptoms by school age. Am J Respir Crit Care Med, 2001, 163: 37-42.
38. Bisgaard H, Jensen SM, Bonnelykke K. Interaction between asthma and lung function growth in early life. Am J Respir Crit Care Med, 2012, 185: 1183-89.
39. Wilson NM, Lamprill JR, Mak JC, Clarke JR, Bush A, Silverman M. Symptoms, lung function, and beta2-adrenoceptor polymorphisms in a birth cohort followed for 10 years. Pediatr Pulmonol, 2004, 38: 75-81.
40. Reiss A, Wigg B, Verburgt L. Morphologic determinants of airway responsiveness in chronic smokers. Am J Respir Crit Care Med, 1996 Nov, 154(5): 1444-1449.
41. Juusela M, Pallasaho P, Rönmark E, Sarna S, Sovijärvi A, Lundbäck B. Dose-dependent association of smoking and bronchial hyperresponsiveness. European Respiratory Journal, 2013 Dec, 42(6): 1503-1512. DOI: 10.1183/09031936.00073712.
42. Eisner MD, Anthonisen N, Coultas D, et al. and the Committee on Nonsmoking COPD, Environmental and Occupational Health Assembly. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2010,182: 693-718.
43. Svanes C, Sunyer J, Plana E et al. Early life origins of chronic obstructive pulmonary disease. Thorax, 2010, 65: 14-20.
44. Beyer D, Mitfessel H, Gillissen A. Maternal smoking promotes chronic obstructive lung disease in the off spring as adults. Eur J Med Res, 2009, 14(suppl 4): 27-31.
45. Breton CV, Byun HM, Wenten M, Pan F, Yang A, Gilliland FD. Prenatal tobacco smoke exposure aff ects global and gene-specifi c DNA methylation. Am J Respir Crit Care Med, 2009, 180: 462-67.
46. Stick SM, Burton PR, Gurrin L, Sly PD, LeSouef PN. Effects of maternal smoking during pregnancy and a family history of asthma on respiratory function in newborn infants. Lancet, 1996, 348: 1060-64.
47. Doruk S, Ozyurt H, Inonu H, Erkorkmaz U, Saylan O, Seyfikli Z. Oxidative status in the lungs associated with tobacco smoke exposure. Clin Chem Lab Med, 2011, 49: 2007-12.
48. Lodrup Carlsen KC, Jaakkola JJ, Nafstad P, Carlsen KH. In utero exposure to cigarette smoking influences lung function at birth. Eur Respir J, 1997, 10: 1774-79.
49. Janson C, Chinn S, Jarvis D, Zock JP, Toren K, Burney P and the European Community Respiratory Health Survey. Effect of passive smoking on respiratory symptoms, bronchial responsiveness, lung function, and total serum IgE in the European Community. Respiratory Health Survey: a cross-sectional study. Lancet, 2001, 358: 2103-09.
50. Simoni M, Baldacci S, Puntoni R et al. Respiratory symptoms/diseases and environmental tobacco smoke (ETS) in never smoker Italian women. Respir Med, 2007, 101: 531-38.
51. Yin P, Jiang CQ, Cheng KK, et al. Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study. Lancet, 2007, 370: 751-57.
52. Taylor DHJr, Hasselblad V, Henley SJ, Thun MJ, Sloan FA. Benefits of smoking cessation for longevity. Am. J. Public Health, 2002, 92: 990- 996.
53. van Schayck CP, Kaper J. Smoking and COPD: will they ever vanish into smoke? (Editorial). Primary Care Respir. J., 2006, 15: 81-83.
54. Xu X, Dockery DW, Ware JH, Speizer FE, Ferris BG. Effects of cigarette smoking on rate of loss of pulmonary function in adults: a longitudinal assessment. Am. Rev. Respir. Dis., 1992, 146: 1345-1348.
55. Di Stefano A, Capelli A, Lusuardi M, Balbo P, Vecchio C, Maestrelli P, Mapp CE, Fabbri LM, Donner CF, Saetta M. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am. J. Respir. Crit. Care Med., 1998, 158: 1277-1285.
56. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WAJr, Enright PL, Kanner RE, O’Hara et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of. decline of FEV 1. The Lung Health Study. JAMA, 1994, 272: 1497-1505.
57. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality. A Randomized Clinical Trial. Ann. Intern. Med., 2005, 142: 233-239.
58. Murray RP, Anthonissen NR, Connett JE, Wise RA, Lindgren PG, Greene PG, Nides MA. Effect of multiple attempts to quit smoking and relapses to smoking on pulmonary function. J. Clin. Epid., 1998, 51: 1317-1326.
59. Kanner RE, Connett JE, Williams DE, Buist AS. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with mild chronic obstructive pulmonary disease. The Lung Health Study. Am. J. Med., 1999, 106: 406-410.
60. Fletcher C, Peto R, Tinker C. The natural history of chronic airflow obstruction. BMJ, 1977, 1: 1645-1648.
61. Xu X, Dockery DW, Ware JH, Speizer FE, Ferris BG. Effects of cigarette smoking on rate of loss of pulmonary function in adults: a longitudinal assessment. Am. Rev. Respir. Dis., 1992, 146: 1345-1348.
62. Wagena EJ, Knipschild P, Huibers MJH, Wouters EFM, van Schayck CP. The efficacy of bupropion and nortriptyline for smoking cessation among people who are at risk for or have chronic obstructive pulmonary disease: a randomizaed, placebo-controlled trial. Arch. Int. Med., 2005, 165: 2286-2292.
63. Zielinszky J, Bednarek M. Early detection of COPD in a high-risk population using spirometric screening. Chest, 2001, 119: 731-736.
64. Stratelis G, Mölstad S, Jakobsson P, Zetterström O. The impact of repeated spirometry and smoking cessation advice on smokers with mild COPD. Scandinavian J. Primary Health Care, 2006, 24: 133-139.
65. Федеральный закон от 23.02.2013 №15-ФЗ «Об охране здоровья граждан от воздействия окружающего табачного дыма и последствий потребления табака». Специализированный правовой сайт КонсультантПлюс. www. consultant.ru.
66. Приказ Минздрава России от 30.09.2015 № 683н «Об утверждении Порядка организации и осуществления профилактики неинфекционных заболеваний и проведения мероприятий по формированию здорового образа жизни в медицинских организациях». (Зарегистрировано в Минюсте России 24.11.2015 № 39822) Специализированный правовой сайт КонсультантПлюс. www.consultant.ru.
67. Приказ Министерства здравоохранения и социального развития РФ от 15 мая 2012 г. №543н «Об утверждении Положения об организации оказания первичной медико-санитарной помощи взрослому населению». с изменениями и дополнениями от: 23 июня, 30 сентября 2015 г. Специализированный правовой сайт КонсультантПлюс. www.consultant.ru.
68. West R, Raw M, McNeill A et al. Health-care interventions to promote and assist tobacco cessation: a review of efficacy, effectiveness and affordability for use in national guideline development. Addiction, 2015, 110: 1388-1403.
69. Stead LF, Bergson G, Lancaster T. Physician advice for smoking cessation. Cochrane Database of Systematic Reviews, 2008, Issue 4.
70. Rose G, Colwell L, Randomised controlled trial of anti-smoking advice: final (20 year) results. Journal of Epidemiology and Community Health, 1992, 46: 75-77.
71. Michie S, Hyder N, Walia A,West R. Development of a taxonomy of behaviour change techniques used in individual behavioural support for smoking cessation. Addict Behav, 2011, 36: 315-9.
72. West R, EvansA, Michie S. Behavior change techniques used in group-based behavioral support by the English stop smoking services and preliminary assessment of association with short-term quit outcomes. Nicotine Tob Res, 2011, 13: 1316-20.
73. Lancaster T, Stead LF, Individual behavioural counselling for smoking cessation (Review). The Cochrane Library, 2008, Issue 4.
74. Stead LF, Lancaster T. Group behaviour therapy programmes for smoking cessation (Review). The Cochrane Library, 2009, Issue 2.
75. Ramos et al. Effectiveness of intensive group and individual interventions for smoking cessation in primary health care settings: a randomized trial. BMC Public Health, 2010.
76. Stead LF, Lancaster T. Behavioural interventions as adjuncts to pharmacotherapy for smoking cessation. Cochrane Database Syst Rev, 2012, 12: CD009670.
77. Stead LF, Hartmann-Boyce J, Perera R, Lancaster T. Telephone counselling for smoking cessation. Cochrane Database Syst Rev, 2013: 8CD002850.
78. Gilbert H, Sutton S. Evaluating the effectiveness of proactive telephone counselling for smoking cessation in a randomized controlled trial. Addiction, 2006, 101: 590-8.
79. Michie S, Free C, West R. Characterising the ‘Txt2Stop’ smoking cessation text messaging intervention in terms of behaviour change techniques. J Smoking Cessation, 2012, 7: 55-60.
80. Whittaker R, McRobbie H, Bullen C, Borland R, Rodgers A, Gu Y. Mobile phone-based interventions for smoking cessation. Cochrane Database Syst Rev, 2012, 11: CD006611.
81. Fiore MC, Bailey WC, Cohen SJ et al. Treating tobacco use and dependence. Clinical Practice Guideline. Rockville, U.S. Department of Health and Human Services, 2008.
82. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev, 2012, 11: CD000146.
83. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev, 2007, 1: CD000031.
84. Khai Tran, Keiko Asakawa et al. Pharmacologicbased Strategies for Smoking Cessation: Clinical and Cost-Effectiveness Analyses, Canadian Agency for Drugs and Technologies in Health, 2010. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3442619/.
85. Инструкция по медицинскому применению препарата Чампикс®, одобрена Росздравнадзором от 18.06.2009 с изменениями от 03.04 2013, 02.08.2013 и 05.03.2014.
86. Vadasz I. The first Hungarian experiences with varenicline to support smoking cessation. Medicina Thoracalis, 2009 February, LXII.1: 1-9.
87. Gonzales D, Rennard SI et al. Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking CessationA Randomized Controlled Trial. JAMA, 2006, 296(1): 47-55. doi:10.1001/jama.296.1.47.
88. Rollema H, Coe J, Chambers L et al. Rationale, pharmacology and clinical efficacy of partial agonists of α4β2 nACh receptors for smoking cessation. Trends Pharmacol Sci, 2007, 28: 316-325.
89. Cahill K et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis (Review). The Cochrane Collaboration and published in The Cochrane Library, 2013, 5: 2.
90. Tønnesen Ph. Smoking cessation and COPD European Respiratory Review, 2013 Mar, 22(127): 37-43. DOI: 10.1183/09059180.00007212.
91. Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev, 2014. 1CD000031.
92. Cahill K, Stead L, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Coch rane Database of Systematic Reviews, 2012. CD006103. doi: 10.1002/14651858. CD006103.pub6.
93. Vinnikov D, Brimkulov N, Burjubaeva A. A double- blind, randomised, placebo-controlled trial of cytisine for smoking cessation in mediumdependent workers. Journal of Smoking Cessation, 2008, 3(1): 57-62.
94. Bader P, McDonald PW, Selby P. An Algorithm for Tailoring Pharmacotherapy for Smoking Cessation: Results from a Delphi Panel of International Experts. Tob. Control, 2008, 13. Doi:10.1136/tc.2008.025635.
95. Tashkin DP, Rennard S, Hays JT, et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest, 2011, 139: 591-599.
Review
For citations:
Gambaryan MG. Chronic respiratory disease and tobacco consumption. Review. Meditsinskiy sovet = Medical Council. 2016;(17):144-152. (In Russ.) https://doi.org/10.21518/2079-701X-2016-17-144-152
Views:
2317
Email this article 